Informa Australia is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Healthcare
Melbourne, 22nd February 2011 - The Australian pharmaceutical industry landscape is set to dramatically alter as a result of government changes to the Pharmaceutical Benefits Scheme (PBS), suggests independent market analyst, Datamonitor. Datamonitor’s outlook for the future includes withdrawn products, a struggling generics sector and wholesaler reorganization, as PBS reforms take effect. Erin Brady, Australian…
23 Feb 2011, by Informa InsightsHealthcare
Melbourne, 18th February 2011. The number of women diagnosed with breast cancer per year in the seven major markets is forecast to increase by 13% over the next decade, finds independent healthcare analyst, Datamonitor.* However, in Japan, breast cancer incidence rates will rise by approximately 24% to 2019 to reach 56,400 cases, compared to 45,600…
18 Feb 2011, by Informa InsightsHealthcare
Melbourne, 10th February 2011 - Strong diabetes growth will not be enough to stop the cardiovascular and metabolic market from declining, finds independent market analyst Datamonitor.* Datamonitor forecasts that the cardiovascular and metabolic market across the seven major markets** will peak in 2011 and then begin to decline, with total sales falling from $105bn in…
10 Feb 2011, by Informa InsightsHealthcare
Melbourne, 8th February 2011 - Indian manufacturers are ideally placed to capitalise on the growing biosimilars market, according to independent market analyst Datamonitor. Although the biosimilars market is in its infancy, Datamonitor research suggests that Indian manufacturers are well positioned to capitalise on the future growth of this market both domestically and internationally. Alistair Sinclair,…
8 Feb 2011, by Informa Insights